mutation, BRAF mutant colon cancers exhibit intrinsic resistance to BRAF inhibitor, vemurafenib [6] . This is attributed to the feedback activation of EGFR, another RTK. To test whether EGFR also mediates acquired resistance in BRAF mutant melanoma cells, Sun et al. [7] first examined paired pre-and post-treatment tumor biopsies of 16 melanoma patients. They found that the expression of EGFR was substantially increased in 6 out of 16 progressing tumor biopsies. 
Because of the rapid decrease in EGFR expression following the removal of vemurafenib, EGFR low melanoma cells may regain sensitivity to vemurafenib. This strategy may benefit a subset of BRAF V600E melanoma patients who have experienced a drug holiday.
Overall, this study has delineated the role of SOX10-TGF-β-EGFR/PDGFRβ/ ERBB3 signaling axis in mediating adaptive and acquired resistance of BRAF V600E melanoma cells to vemurafenib. Targeting EGFR alone with EGFR inhibitor, Gefitinib, has not completely counteracted acquired resistance, implying the redundancy of multiple RTKs. However, combination of vemurafenib and PI3K inhibitor, GDC0941, was effective in inhibiting RTKs-mediated acquired resistance, underscoring the importance of targeting core acquired resistance mechanism including the PI3K pathway.
It is not entirely clear whether vemurafenib directly or indirectly suppresses SOX10 expression. The authors hypothesize that vemurafenib enriches a subpopulation of senescent SOX10 low / EGFR high melanoma cells which outgrow when the MAPK pathway is decreased to a certain threshold. This hypothesis resonates with progression of human senescent nevi into primary melanomas but warrants further investigation. It has been reported that vemurafenib by itself can induce cellular senescence in BRAF V600E melanoma cells [8] . It is not yet clear whether the SOX10-TGF-β-EGFR/PDGFRβ/ERBB3 signaling axis also plays a role in senescent cells.
Depletion of SOX10 led to the decrease in MITF expression, which is another important melanocyte lineage gene. However, MITF can also confer resistance to vemurafenib [9, 10] 
